Dr. Reddy’s (RDY) and Alvotech (ALVO) announced that the FDA has accepted a 351(k) biologic license application submission for AVT03, developed by Alvotech, a proposed biosimilar of Prolia and Xgeva.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDY:
- Dr. Reddy’s, Alvotech announce FDA acceptance of BLA for AVT03
- Dr. Reddy’s Recalls Mislabelled Levetiracetam Injection in U.S.
- Dr. Reddy’s announces recall of Levetiracetam 0.75% Sodium Chloride injection
- Dr. Reddy’s Laboratories to Engage with Investors at Upcoming Conference
- Dr. Reddy’s Faces Tax Penalty, Evaluates Appeal